Vaccinex Inc.

NASDAQ: VCNXHealthcare / Biotechnology / USA
7.31+0.7600+11.60%Vol 8 3721Y Perf -18.54%
Sep 20th, 2019 16:00
BID7.00 ASK7.60
Open6.55 Previous Close6.55
Pre-Market- After-Trading-
 - -%  - -%
Target Price
22.00 
Analyst Rating
Strong Buy 1.00
Potencial %
200.96 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12M
100/100/100 
Value Ranking
 —    -
Insiders Value % 3/6/12M
100/100/100 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12M
100/100/100 
Income Ranking
 —    -
Market Cap (mil)109 
Earnings Rating
Sell
Price Range Ratio 52wk %
64.88 
Earnings Date
12th Nov 2019

Today's Price Range

6.557.36

52wk Range

3.329.47

Summary:

Buy

Technical Indicators: Neutral
Moving Averages: Strong Buy
Performance
1 Week
22.45%
1 Month
41.94%
3 Months
37.41%
6 Months
49.18%
1 Year
-18.54%
3 Years
-
5 Years
-
10 Years
-

Name / TickerPriceChg.Chg.%
VCNX7.310.760011.60
AAPL217.73-3.2300-1.46
GOOG1 229.93-8.7800-0.71
MSFT139.44-1.6300-1.16
XOM72.08-0.2500-0.35
WFC48.63-0.2800-0.57
JNJ131.651.54001.18
FB189.93-0.2100-0.11
GE9.37-0.0500-0.53
JPM118.90-0.4800-0.40
Earnings HistoryEstimateReportedSurprise %
Q02 2019-0.70-0.77-10.00
Q01 2019-0.68-0.79-16.18
Q03 2018-0.58-0.93-60.34
----
----
----
----
----
Earnings Per EndEstimateRevision %Trend
9/2019 QR-0.53-6.00Negative
12/2019 QR-0.52-36.84Negative
12/2019 FY-2.60-10.64Negative
12/2020 FY-2.04-1.49Negative
Next Report Date12th Nov 2019
Estimated EPS Next Report-0.53
Estimates Count1
EPS Growth Next 5 Years %-
Volume Overview
Volume8 372
Shares Outstanding (in ths.)14 863
Trades Count6
Dollar Volume2 956
Avg. Volume8 991
Avg. Weekly Volume5 190
Avg. Monthly Volume3 687
Avg. Quarterly Volume5 744
Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
2 (100.00 %)
2 (100.00 %)
2 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Vaccinex Inc.

Vaccinex Inc is a clinical-stage biotechnology company. It is engaged in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders. The company's lead platform technologies include SEMA4D antibody platform and ActivMAb antibody discovery platform. Its lead product candidate VX15 is in clinical development for the treatment of NSCLC, osteosarcoma and Huntington's disease and additional product candidates VX5 and VX25 are in earlier stages of development.

CEO: Maurice Zauderer

Teplephone: +1 585 271-2700

Address: 1895 Mount Hope Avenue, Rochester 14620, NY, USA

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

100%0%

Bearish Bullish

67%33%

Bearish Bullish

50%50%

Bearish Bullish

46%54%

News